Phase 3b, Randomized, Open-Label Study Of Bevacizumab + Temsirolimus Vs. Bevacizumab + Interferon-Alfa As First-Line Treatment In Subjects With Advanced Renal Cell Carcinoma

Trial Profile

Phase 3b, Randomized, Open-Label Study Of Bevacizumab + Temsirolimus Vs. Bevacizumab + Interferon-Alfa As First-Line Treatment In Subjects With Advanced Renal Cell Carcinoma

Completed
Phase of Trial: Phase III

Latest Information Update: 24 Aug 2016

At a glance

  • Drugs Temsirolimus (Primary) ; Bevacizumab; Interferon alpha-2a
  • Indications Renal cell carcinoma
  • Focus Registrational; Therapeutic Use
  • Acronyms INTORACT
  • Sponsors Pfizer; Wyeth
  • Most Recent Events

    • 22 Jul 2015 Status changed from active, no longer recruiting to completed as per ClinicalTrials.gov record.
    • 08 Jun 2015 Planned End Date changed from 1 Apr 2015 to 1 Sep 2015 as reported ClinicalTrials.gov record.
    • 11 Dec 2014 Planned End Date changed from 1 Mar 2015 to 1 Apr 2015 as per ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top